Compare AbbVie Inc (ABBV) vs Pinterest Inc (PINS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Pinterest Inc — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Pinterest Inc trades at $22.18 (market cap $12.56B). The key difference: AbbVie Inc is far larger — about 35.8× Pinterest Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Pinterest Inc pays none. Which is the better fit depends on your goals.
| ABBV | PINS | |
|---|---|---|
Market Cap | $449.91B | $12.56B |
Sector | Health | Media |
52-Week High | $261.07 | $39.17 |
52-Week Low | $184.85 | $15.42 |
Enterprise Value | $513.38B | $12.47B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Pinterest (PINS) trades at $22.42, up 1.59% with a bullish technical outlook. The company shows strong revenue growth from $2.8B in 2022 to $4.2B in 2025, though net income margin declined to 7.64% in 2026. Recent AI shopping initiatives and Amazon integration highlight strategic moves to boost monetization. Analyst consensus is bullish with a $27.82 price target, representing 24% upside potential from current levels.
PINS presents a growth opportunity with improving fundamentals and strong analyst support, but faces execution risks in monetizing its user base. The stock's elevated P/E ratio of 46.35 requires sustained earnings growth to justify valuation. Competitive pressures in social media and dependency on advertising revenue remain key challenges for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →
